Viewing Study NCT05557903

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 7:37 PM
Ignite Modification Date: 2025-12-30 @ 1:32 AM
Study NCT ID: NCT05557903
Status: UNKNOWN
Last Update Posted: 2022-09-28
First Post: 2022-02-19
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL
Sponsor: Lanzhou Institute of Biological Products Co., Ltd
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Lymphoma, Non-Hodgkin View
None Lymphoma, T-Cell View
Keywords:

Keywords

Keyword Brief Keyword Text View
None anti-CD52 monoclonal antibody View
None relapsed and refractory View